What you’re overlooking is that the overhang to MNTA’s share price from Teva’s Lovenox program is now essentially gone.
If by some chance Teva actually got FDA approval, MNTA’s lawsuit against Teva (which has already been filed) would likely play out in a manner similar to MNTA’s lawsuit against Amphastar.
"A less important point is that it's also true that amphastar got FDA approval without violating the 466 patent . . ."
This is not established. Momenta chose not to argue that patent because the limited discovery did not give them enough information to argue it conclusively. With the full discovery that will attend the trial, the '466 patent might very well be in play.
Market Data 
Markets 
AI
